News
FDA takes U-turn on Sarepta's Elevidys, backing Duchenne gene therapy again in ambulatory patients
Monday, the FDA said Sarepta may resume treating ambulatory DMD patients with Elevidys. The recommendation comes just 10 days after the agency requested that the company halt all shipments of the one-time treatment following reports of three deaths among patients who had received a Sarepta gene therapy, including two on Elevidys.
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
The agency’s now-reversed decision to halt distribution of a gene therapy for children suffering from muscular dystrophy ...
Duchenne muscular dystrophy, also known as DMD, is a genetic, progressive condition that causes loss of muscle function over time. It’s mostly seen in boys and men, but it can also occur, often ...
Duchenne muscular dystrophy is rare Duchenne is a rare, progressive disorder in which muscle cells are in a constant state of destruction. Need a break? Play the USA TODAY Daily Crossword Puzzle.
Duchenne Muscular Dystrophy affects 12,000 to 15,000 children and young adults in the United States and about 300,000 worldwide. It's caused by a mutation in the dystrophin gene, which makes a ...
Duchenne Muscular Dystrophy may no longer be a death sentence. Oct. 17, 2012— -- Although he made it to 29 years old with Duchenne muscular dystrophy, Jason Williams was not expected to ...
Lancashire Evening Post on MSN1d
Cumbria family’s ‘Iron Will’ triathlon for son living with muscular dystrophyOn Thursday 28 August, Sam Taylor, 46, his wife Sue, 47, and daughter Beth, 17, from Crooklands in Cumbria will set off to ...
MyHealthTeam, a Swoop company, the creator of one of the largest, engaged patient social networks in healthcare, has announced the launch of myMDteam. This new website and patient community is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback